WO2003057916A3 - Cancer profiles - Google Patents

Cancer profiles Download PDF

Info

Publication number
WO2003057916A3
WO2003057916A3 PCT/IB2003/000360 IB0300360W WO03057916A3 WO 2003057916 A3 WO2003057916 A3 WO 2003057916A3 IB 0300360 W IB0300360 W IB 0300360W WO 03057916 A3 WO03057916 A3 WO 03057916A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
cancers
present
cancer profiles
profiles
Prior art date
Application number
PCT/IB2003/000360
Other languages
French (fr)
Other versions
WO2003057916A2 (en
Inventor
Toyomasa Katagiri
Yasuyuki Ohnishi
Yusuke Nakamura
Original Assignee
Riken Inst Of Physical And Che
Toyomasa Katagiri
Yasuyuki Ohnishi
Yusuke Nakamura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken Inst Of Physical And Che, Toyomasa Katagiri, Yasuyuki Ohnishi, Yusuke Nakamura filed Critical Riken Inst Of Physical And Che
Priority to JP2003558209A priority Critical patent/JP2005532036A/en
Priority to AU2003201741A priority patent/AU2003201741A1/en
Priority to EP03700442A priority patent/EP1466016A2/en
Publication of WO2003057916A2 publication Critical patent/WO2003057916A2/en
Publication of WO2003057916A3 publication Critical patent/WO2003057916A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to genetic profiles and markers of cancers and provides systems and methods for screening drugs that are effective for specific patients and types of cancers, In particular, the present invention provides personalized treatment customized to an individual's cancer.
PCT/IB2003/000360 2002-01-09 2003-01-09 Cancer profiles WO2003057916A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003558209A JP2005532036A (en) 2002-01-09 2003-01-09 Cancer profile
AU2003201741A AU2003201741A1 (en) 2002-01-09 2003-01-09 Cancer profiles
EP03700442A EP1466016A2 (en) 2002-01-09 2003-01-09 Cancer profiles

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34695202P 2002-01-09 2002-01-09
US60/346,952 2002-01-09
US10/339,533 US20030165954A1 (en) 2002-01-09 2003-01-09 Cancer profiles

Publications (2)

Publication Number Publication Date
WO2003057916A2 WO2003057916A2 (en) 2003-07-17
WO2003057916A3 true WO2003057916A3 (en) 2004-04-22

Family

ID=32867892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/000360 WO2003057916A2 (en) 2002-01-09 2003-01-09 Cancer profiles

Country Status (5)

Country Link
US (1) US20030165954A1 (en)
EP (2) EP1466016A2 (en)
JP (1) JP2005532036A (en)
AU (1) AU2003201741A1 (en)
WO (1) WO2003057916A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1270736B1 (en) * 2000-03-24 2009-03-11 FUJIFILM Corporation Films for assaying protease activity
US20030198961A1 (en) * 2002-04-15 2003-10-23 Spelsberg Thomas C. Determining cancer aggressiveness
US20050208010A1 (en) * 2002-07-10 2005-09-22 L'oreal Genes from Chromosome 3, 5 and 11 involved in premature canities
WO2004029219A2 (en) * 2002-09-27 2004-04-08 Cold Spring Harbor Laboratory Cell-based rna interference and related methods and compositions
US9811818B1 (en) * 2002-10-01 2017-11-07 World Award Academy, World Award Foundation, Amobilepay, Inc. Wearable personal digital device for facilitating mobile device payments and personal use
US9704154B2 (en) * 2002-10-01 2017-07-11 World Award Academy, World Award Foundation, Amobilepay, Inc. Wearable personal digital device for facilitating mobile device payments and personal use
US7465542B2 (en) * 2002-10-15 2008-12-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining risk of treatment toxicity
CN1867679B (en) * 2003-07-17 2012-10-03 环太平洋生物技术有限公司 Markers for detection of gastric cancer
US20050142585A1 (en) * 2003-10-02 2005-06-30 University Of South Florida Determination of phenotype of cancer and of precancerous tissue
DE602004018819D1 (en) * 2003-10-29 2009-02-12 Kumamoto Tech & Ind Found Diagnostic procedure for malignant melanoma
ES2636470T3 (en) 2004-04-09 2017-10-05 Genomic Health, Inc. Gene expression markers to predict response to chemotherapy
GB0412620D0 (en) * 2004-06-05 2004-07-07 Univ Belfast BRCA1 markers
CA2572154A1 (en) * 2004-06-30 2006-03-30 Paul L. Deangelis Methods of selectively treating diseases with specific glycosaminoglycan polymers
JP2008523816A (en) * 2004-12-15 2008-07-10 ベス イスラエル ディーコネス メディカル センター Nucleic acids and polypeptides useful for the diagnosis and treatment of pregnancy complications
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
AU2006235258A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes
CA2604549A1 (en) 2005-04-13 2006-10-19 Oncotest Gmbh Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
EP1724585A1 (en) * 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment
EP1724586A3 (en) * 2005-05-21 2007-07-04 ProteoSys AG Annexin for cancer risk assessment
JP2009502115A (en) * 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 Diagnostic method for small cell lung cancer
WO2007038792A2 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
US20090181852A1 (en) * 2005-11-15 2009-07-16 Inverness Medical Switerland Gmbh Assays
US8700335B2 (en) * 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
EP2423332A1 (en) * 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
EP2009114A1 (en) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
WO2009102957A2 (en) * 2008-02-14 2009-08-20 The Johns Hopkins University Methods to connect gene set expression profiles to drug sensitivity
ES2717908T3 (en) 2010-06-14 2019-06-26 Lykera Biomed S A Antibodies S100A4 and therapeutic uses thereof
KR20130138779A (en) * 2010-09-23 2013-12-19 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 Top2a inhibition by temozolomide useful for predicting gbm patient's survival
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US8715937B2 (en) 2010-11-15 2014-05-06 Exact Sciences Corporation Mutation detection assay
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CN103890587A (en) * 2011-08-31 2014-06-25 昂科赛特公司 Methods and compositions for the treatment and diagnosis of cancer
US9127318B2 (en) 2011-10-18 2015-09-08 Exact Sciences Corporation Multiplexed KRAS mutation detection assay
SG11201505852YA (en) * 2013-01-29 2015-08-28 Molecular Health Gmbh Systems and methods for clinical decision support
EP3198030B1 (en) 2014-09-26 2020-11-04 HI-STEM gGmbH Im Deutschen Krebsforschungszentrum DKFZ Novel methods for sub-typing and treating cancer
US11153156B2 (en) 2017-11-03 2021-10-19 Vignet Incorporated Achieving personalized outcomes with digital therapeutic applications
US10521557B2 (en) 2017-11-03 2019-12-31 Vignet Incorporated Systems and methods for providing dynamic, individualized digital therapeutics for cancer prevention, detection, treatment, and survivorship
US11158423B2 (en) 2018-10-26 2021-10-26 Vignet Incorporated Adapted digital therapeutic plans based on biomarkers
US10762990B1 (en) 2019-02-01 2020-09-01 Vignet Incorporated Systems and methods for identifying markers using a reconfigurable system
US11056242B1 (en) 2020-08-05 2021-07-06 Vignet Incorporated Predictive analysis and interventions to limit disease exposure
US11127506B1 (en) 2020-08-05 2021-09-21 Vignet Incorporated Digital health tools to predict and prevent disease transmission
US11456080B1 (en) 2020-08-05 2022-09-27 Vignet Incorporated Adjusting disease data collection to provide high-quality health data to meet needs of different communities
US11504011B1 (en) 2020-08-05 2022-11-22 Vignet Incorporated Early detection and prevention of infectious disease transmission using location data and geofencing
US11281553B1 (en) 2021-04-16 2022-03-22 Vignet Incorporated Digital systems for enrolling participants in health research and decentralized clinical trials
US11586524B1 (en) 2021-04-16 2023-02-21 Vignet Incorporated Assisting researchers to identify opportunities for new sub-studies in digital health research and decentralized clinical trials
US11789837B1 (en) 2021-02-03 2023-10-17 Vignet Incorporated Adaptive data collection in clinical trials to increase the likelihood of on-time completion of a trial
US11901083B1 (en) 2021-11-30 2024-02-13 Vignet Incorporated Using genetic and phenotypic data sets for drug discovery clinical trials
US11705230B1 (en) 2021-11-30 2023-07-18 Vignet Incorporated Assessing health risks using genetic, epigenetic, and phenotypic data sources

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846717A (en) * 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5994069A (en) 1996-01-24 1999-11-30 Third Wave Technologies, Inc. Detection of nucleic acids by multiple sequential invasive cleavages
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
CA2148252C (en) 1992-10-30 2007-06-12 Roger Brent Interaction trap system for isolating novel proteins
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
AU6044994A (en) 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
ATE336587T1 (en) 1994-06-10 2006-09-15 Genvec Inc ADENOVIRUS VECTOR SYSTEMS AND CELL LINES
DK0787200T3 (en) 1994-10-28 2005-08-15 Univ Pennsylvania Improved adenovirus and methods for its use
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US6019978A (en) 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
KR100449181B1 (en) 1995-06-15 2005-01-24 크루셀 홀란드 비.브이. A recombinant adenovirus packaging system that can be used in gene therapy
CA2239957A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5985557A (en) 1996-01-24 1999-11-16 Third Wave Technologies, Inc. Invasive cleavage of nucleic acids
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
ATE363652T1 (en) 1997-03-07 2007-06-15 Clare Chemical Res Inc FLUOROMETRIC DETECTION WITH VISIBLE LIGHT
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
NZ500657A (en) 1997-07-11 2002-11-26 Introgene B Interleukin-3 gene therapy for cancer
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
JP2003528029A (en) 1998-08-14 2003-09-24 アヴェンティス ファーマシューティカルズ インコーポレイテッド Adenovirus formulations for gene therapy
AU773202B2 (en) 1998-08-27 2004-05-20 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
US6801859B1 (en) * 1998-12-23 2004-10-05 Rosetta Inpharmatics Llc Methods of characterizing drug activities using consensus profiles
JP3617373B2 (en) * 1999-06-03 2005-02-02 オムロン株式会社 Gate device
JP3825222B2 (en) * 2000-03-24 2006-09-27 松下電器産業株式会社 Personal authentication device, personal authentication system, and electronic payment system
AU2001268513A1 (en) 2000-06-17 2002-01-02 Third Wave Technologies, Inc. Nucleic acid accessible hybridization sites
IL155245A0 (en) * 2000-10-12 2003-11-23 Ferring Bv Novel serine protease genes related to dppiv
US6867683B2 (en) * 2000-12-28 2005-03-15 Unisys Corporation High security identification system for entry to multiple zones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846717A (en) * 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BEYER-SEHLMEYER G ET AL: "Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin.", EUROPEAN JOURNAL OF CANCER, vol. 35, no. 12, November 1999 (1999-11-01), pages 1735 - 1742, XP002254039, ISSN: 0959-8049 *
COLLIE-DUGUID E S R ET AL: "Cloning and initial characterization of the human DPYD gene promoter.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 271, no. 1, 29 April 2000 (2000-04-29), pages 28 - 35, XP002255521, ISSN: 0006-291X *
GREEN A R ET AL: "Comparisons of the effects of tamoxifen, toremifene and raloxifene on enzyme induction and gene expression in the ovariectomised rat uterus.", JOURNAL OF ENDOCRINOLOGY, vol. 170, no. 3, September 2001 (2001-09-01), pages 555 - 564, XP002254037, ISSN: 0022-0795 *
HILSENBECK S G ET AL: "Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.", JOURNAL OF THE NATIONAL CANCER INSTITUTE. UNITED STATES 3 MAR 1999, vol. 91, no. 5, 3 March 1999 (1999-03-03), pages 453 - 459, XP009002755, ISSN: 0027-8874 *
See also references of EP1466016A2 *
TAKECHI T ET AL: "Screening of differentially expressed genes in 5-fluorouracil-resistant human gastrointestinal tumor cells.", JAPANESE JOURNAL OF CANCER RESEARCH: GANN. JAPAN JUN 2001, vol. 92, no. 6, June 2001 (2001-06-01), pages 696 - 703, XP002254038, ISSN: 0910-5050 *
UEYAMA YOSHITO ET AL: "In vivo chemosensitivity of human malignant cystosarcoma phyllodes xenografts.", ONCOLOGY REPORTS, vol. 7, no. 2, March 2000 (2000-03-01), pages 257 - 260, XP008021860, ISSN: 1021-335X *

Also Published As

Publication number Publication date
WO2003057916A2 (en) 2003-07-17
AU2003201741A1 (en) 2003-07-24
US20030165954A1 (en) 2003-09-04
EP1953244A1 (en) 2008-08-06
JP2005532036A (en) 2005-10-27
EP1466016A2 (en) 2004-10-13

Similar Documents

Publication Publication Date Title
WO2003057916A3 (en) Cancer profiles
WO2003087831A3 (en) Proteins involved in breast cancer
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2004006858A3 (en) Compounds, compositions, and methods employing same
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2004000102A3 (en) Method for predicting response to epidermal growth factor receptor-directed therapy
WO2002099054A3 (en) Hccss as modifiers of the p53 pathway and methods of use
AU2003220317A1 (en) Methods and drug delivery systems for the treatment of orofacial diseases
WO2002088170A3 (en) Cripto blocking antibodies and uses thereof
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
EP1676132A4 (en) System and method for the treatment of cancer, including cancers of the central nervous system
WO2004041212A3 (en) Apkc isoforms in nervous system disorders and cancer
AU2003217397A1 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
AU2003245927A1 (en) Target genes for the diagnosis and treatment of cancer
WO2004005540A3 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
UA85187C2 (en) 2-aminobenzoyl derivatives
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
AU2003222326A1 (en) Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases
AU2003263036A1 (en) SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003558209

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003700442

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003700442

Country of ref document: EP